Skip to main content
Erschienen in: Medical Oncology 8/2017

01.08.2017 | Original Paper

Impact of venous invasion on the efficacy of adjuvant chemotherapy in elderly patients with stage III colorectal cancer

verfasst von: Nobuaki Hoshino, Kenji Kawada, Koya Hida, Saori Goto, Ryuji Uozumi, Suguru Hasegawa, Kenichi Sugihara, Yoshiharu Sakai

Erschienen in: Medical Oncology | Ausgabe 8/2017

Einloggen, um Zugang zu erhalten

Abstract

One of the reasons for the underuse of adjuvant chemotherapy in elderly patients with stage III colorectal cancer is a small survival benefit. This retrospective study sought to identify the predictive factors for elderly patients who could obtain a sufficient survival benefit. We reviewed the data of 1354 elderly patients (aged ≥70 years) with stage III colorectal cancer who underwent complete resection between January 1997 and December 2006. The efficacy of adjuvant chemotherapy was assessed, and the risk factors for recurrence were determined. The efficacy of adjuvant chemotherapy was also assessed after stratification for the above-mentioned risk factors for recurrence. There was a tendency for adjuvant chemotherapy to be effective in elderly patients (hazard ratio 0.84; 95% CI 0.70–1.01). Age, tumor location, pathology findings, tumor depth, venous invasion and lymph node metastasis were identified to be independent risk factors for recurrence by univariate and multivariate analyses. Among these factors, adjuvant chemotherapy was much effective in the elderly patients with high venous invasion (v2-3) (hazard ratio 0.69; 95% CI 0.52–0.91). High venous invasion (v2-3) was identified to be a predictive factor for elderly patients with stage III colorectal cancer who gained a sufficient survival benefit.
Literatur
1.
Zurück zum Zitat Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66:683–91.CrossRefPubMed Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66:683–91.CrossRefPubMed
3.
Zurück zum Zitat Papamichael D, Audisio RA, Glimelius B, de Gramont A, Glynne-Jones R, Haller D, et al. Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013. Ann Oncol. 2015;26:463–76.CrossRefPubMed Papamichael D, Audisio RA, Glimelius B, de Gramont A, Glynne-Jones R, Haller D, et al. Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013. Ann Oncol. 2015;26:463–76.CrossRefPubMed
4.
Zurück zum Zitat Wilkinson NW, Yothers G, Lopa S, Costantino JP, Petrelli NJ, Wolmark N. Long-term survival results of surgery alone versus surgery plus 5-fluorouracil and leucovorin for stage II and stage III colon cancer: pooled analysis of NSABP C-01 through C-05. A baseline from which to compare modern adjuvant trials. Ann Surg Oncol. 2010;17:959–66.CrossRefPubMedPubMedCentral Wilkinson NW, Yothers G, Lopa S, Costantino JP, Petrelli NJ, Wolmark N. Long-term survival results of surgery alone versus surgery plus 5-fluorouracil and leucovorin for stage II and stage III colon cancer: pooled analysis of NSABP C-01 through C-05. A baseline from which to compare modern adjuvant trials. Ann Surg Oncol. 2010;17:959–66.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Yothers G, O’Connell MJ, Allegra CJ, Kuebler JP, Colangelo LH, Petrelli NJ, et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol. 2011;29:3768–74.CrossRefPubMedPubMedCentral Yothers G, O’Connell MJ, Allegra CJ, Kuebler JP, Colangelo LH, Petrelli NJ, et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol. 2011;29:3768–74.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Sargent DJ, Goldberg RM, Jacobson SD, Macdonald JS, Labianca R, Haller DG, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med. 2001;345:1091–7.CrossRefPubMed Sargent DJ, Goldberg RM, Jacobson SD, Macdonald JS, Labianca R, Haller DG, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med. 2001;345:1091–7.CrossRefPubMed
7.
Zurück zum Zitat Chang HJ, Lee KW, Kim JH, Bang SM, Kim YJ, Kim DW, et al. Adjuvant capecitabine chemotherapy using a tailored-dose strategy in elderly patients with colon cancer. Ann Oncol. 2012;23:911–8.CrossRefPubMed Chang HJ, Lee KW, Kim JH, Bang SM, Kim YJ, Kim DW, et al. Adjuvant capecitabine chemotherapy using a tailored-dose strategy in elderly patients with colon cancer. Ann Oncol. 2012;23:911–8.CrossRefPubMed
8.
Zurück zum Zitat Ko JJ, Kennecke HF, Lim HJ, Renouf DJ, Gill S, Woods R, et al. Reasons for underuse of adjuvant chemotherapy in elderly patients with stage III colon cancer. Clin Colorectal Cancer. 2016;15:179–85.CrossRefPubMed Ko JJ, Kennecke HF, Lim HJ, Renouf DJ, Gill S, Woods R, et al. Reasons for underuse of adjuvant chemotherapy in elderly patients with stage III colon cancer. Clin Colorectal Cancer. 2016;15:179–85.CrossRefPubMed
9.
Zurück zum Zitat Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370:2020–9.CrossRefPubMed Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370:2020–9.CrossRefPubMed
10.
Zurück zum Zitat Watanabe T, Itabashi M, Shimada Y, Tanaka S, Ito Y, Ajioka Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. Int J Clin Oncol. 2012;17:1–29.CrossRefPubMed Watanabe T, Itabashi M, Shimada Y, Tanaka S, Ito Y, Ajioka Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. Int J Clin Oncol. 2012;17:1–29.CrossRefPubMed
11.
Zurück zum Zitat Japanese Society for Cancer of the Colon and Rectum. Japanese Classification of Colorectal Carcinoma Second English Edition. Tokyo: Kanehara, 2009. Japanese Society for Cancer of the Colon and Rectum. Japanese Classification of Colorectal Carcinoma Second English Edition. Tokyo: Kanehara, 2009.
12.
Zurück zum Zitat Yang L, Ma Q, Yu YY, Wang C, Meng WJ, Adell G, et al. Efficacy of surgery and adjuvant therapy in older patients with colorectal cancer: a STROBE-compliant article. Medicine (Baltimore). 2014;93:e266.CrossRef Yang L, Ma Q, Yu YY, Wang C, Meng WJ, Adell G, et al. Efficacy of surgery and adjuvant therapy in older patients with colorectal cancer: a STROBE-compliant article. Medicine (Baltimore). 2014;93:e266.CrossRef
13.
Zurück zum Zitat Wildes TM, Kallogjeri D, Powers B, Vlahiotis A, Mutch M, Spitznagel EL Jr, et al. The benefit of adjuvant chemotherapy in elderly patients with stage III colorectal cancer is independent of age and comorbidity. J Geriatr Oncol. 2010;1:48–56.CrossRefPubMedPubMedCentral Wildes TM, Kallogjeri D, Powers B, Vlahiotis A, Mutch M, Spitznagel EL Jr, et al. The benefit of adjuvant chemotherapy in elderly patients with stage III colorectal cancer is independent of age and comorbidity. J Geriatr Oncol. 2010;1:48–56.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Haller DG, O’Connell MJ, Cartwright TH, Twelves CJ, McKenna EF, Sun W, et al. Impact of age and medical comorbidity on adjuvant treatment outcomes for stage III colon cancer: a pooled analysis of individual patient data from four randomized, controlled trials. Ann Oncol. 2015;26:715–24.CrossRefPubMedPubMedCentral Haller DG, O’Connell MJ, Cartwright TH, Twelves CJ, McKenna EF, Sun W, et al. Impact of age and medical comorbidity on adjuvant treatment outcomes for stage III colon cancer: a pooled analysis of individual patient data from four randomized, controlled trials. Ann Oncol. 2015;26:715–24.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Kim KY, Cha IH, Ahn JB, Kim NK, Rha SY, Chung HC, et al. Estimating the adjuvant chemotherapy effect in elderly stage II and III colon cancer patients in an observational study. J Surg Oncol. 2013;107:613–8.CrossRefPubMed Kim KY, Cha IH, Ahn JB, Kim NK, Rha SY, Chung HC, et al. Estimating the adjuvant chemotherapy effect in elderly stage II and III colon cancer patients in an observational study. J Surg Oncol. 2013;107:613–8.CrossRefPubMed
16.
Zurück zum Zitat Zuckerman IH, Rapp T, Onukwugha E, Davidoff A, Choti MA, Gardner J, et al. Effect of age on survival benefit of adjuvant chemotherapy in elderly patients with stage III colon cancer. J Am Geriatr Soc. 2009;57:1403–10.CrossRefPubMed Zuckerman IH, Rapp T, Onukwugha E, Davidoff A, Choti MA, Gardner J, et al. Effect of age on survival benefit of adjuvant chemotherapy in elderly patients with stage III colon cancer. J Am Geriatr Soc. 2009;57:1403–10.CrossRefPubMed
17.
Zurück zum Zitat Haller DG, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E, et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol. 2011;29:1465–71.CrossRefPubMed Haller DG, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E, et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol. 2011;29:1465–71.CrossRefPubMed
18.
Zurück zum Zitat Twelves C, Scheithauer W, McKendrick J, Seitz JF, Van Hazel G, Wong A, et al. Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy. Ann Oncol. 2012;23:1190–7.CrossRefPubMed Twelves C, Scheithauer W, McKendrick J, Seitz JF, Van Hazel G, Wong A, et al. Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy. Ann Oncol. 2012;23:1190–7.CrossRefPubMed
19.
Zurück zum Zitat Huang J, Nair SG, Mahoney MR, Nelson GD, Shields AF, Chan E, et al. Comparison of FOLFIRI with or without cetuximab in patients with resected stage III colon cancer; NCCTG (Alliance) intergroup trial N0147. Clin Colorectal Cancer. 2014;13:100–9.CrossRefPubMed Huang J, Nair SG, Mahoney MR, Nelson GD, Shields AF, Chan E, et al. Comparison of FOLFIRI with or without cetuximab in patients with resected stage III colon cancer; NCCTG (Alliance) intergroup trial N0147. Clin Colorectal Cancer. 2014;13:100–9.CrossRefPubMed
20.
Zurück zum Zitat Taieb J, Tabernero J, Mini E, Subtil F, Folprecht G, Van Laethem JL, et al. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15:862–73.CrossRefPubMed Taieb J, Tabernero J, Mini E, Subtil F, Folprecht G, Van Laethem JL, et al. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15:862–73.CrossRefPubMed
21.
Zurück zum Zitat Shimada Y, Hamaguchi T, Mizusawa J, Saito N, Kanemitsu Y, Takiguchi N, et al. Randomised phase III trial of adjuvant chemotherapy with oral uracil and tegafur plus leucovorin versus intravenous fluorouracil and levofolinate in patients with stage III colorectal cancer who have undergone Japanese D2/D3 lymph node dissection: final results of JCOG0205. Eur J Cancer. 2014;50:2231–40.CrossRefPubMed Shimada Y, Hamaguchi T, Mizusawa J, Saito N, Kanemitsu Y, Takiguchi N, et al. Randomised phase III trial of adjuvant chemotherapy with oral uracil and tegafur plus leucovorin versus intravenous fluorouracil and levofolinate in patients with stage III colorectal cancer who have undergone Japanese D2/D3 lymph node dissection: final results of JCOG0205. Eur J Cancer. 2014;50:2231–40.CrossRefPubMed
22.
Zurück zum Zitat Yoshida M, Ishiguro M, Ikejiri K, Mochizuki I, Nakamoto Y, Kinugasa Y, et al. S-1 as adjuvant chemotherapy for stage III colon cancer: a randomized phase III study (ACTS-CC trial). Ann Oncol. 2014;25:1743–9.CrossRefPubMedPubMedCentral Yoshida M, Ishiguro M, Ikejiri K, Mochizuki I, Nakamoto Y, Kinugasa Y, et al. S-1 as adjuvant chemotherapy for stage III colon cancer: a randomized phase III study (ACTS-CC trial). Ann Oncol. 2014;25:1743–9.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Schmoll HJ, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E, et al. Capecitabine plus oxaliplatin compared with fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results of the NO16968 randomized controlled phase III trial. J Clin Oncol. 2015;33:3733–40.CrossRefPubMed Schmoll HJ, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E, et al. Capecitabine plus oxaliplatin compared with fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results of the NO16968 randomized controlled phase III trial. J Clin Oncol. 2015;33:3733–40.CrossRefPubMed
24.
Zurück zum Zitat Shinto E, Tsuda H, Ueno H, Shimazaki H, Yamamoto J, Hase K. Prognostic value of the number and size of venous invasions in pT3 colorectal cancer: a prospective observational study. World J Surg. 2014;38:3257–64.CrossRefPubMed Shinto E, Tsuda H, Ueno H, Shimazaki H, Yamamoto J, Hase K. Prognostic value of the number and size of venous invasions in pT3 colorectal cancer: a prospective observational study. World J Surg. 2014;38:3257–64.CrossRefPubMed
25.
Zurück zum Zitat Roxburgh CS, McMillan DC, Richards CH, Atwan M, Anderson JH, Harvey T, et al. The clinical utility of the combination of T stage and venous invasion to predict survival in patients undergoing surgery for colorectal cancer. Ann Surg. 2014;259:1156–65.CrossRefPubMed Roxburgh CS, McMillan DC, Richards CH, Atwan M, Anderson JH, Harvey T, et al. The clinical utility of the combination of T stage and venous invasion to predict survival in patients undergoing surgery for colorectal cancer. Ann Surg. 2014;259:1156–65.CrossRefPubMed
26.
Zurück zum Zitat Gibson KM, Chan C, Chapuis PH, Dent OF, Bokey L. Mural and extramural venous invasion and prognosis in colorectal cancer. Dis Colon Rectum. 2014;57:916–26.CrossRefPubMed Gibson KM, Chan C, Chapuis PH, Dent OF, Bokey L. Mural and extramural venous invasion and prognosis in colorectal cancer. Dis Colon Rectum. 2014;57:916–26.CrossRefPubMed
Metadaten
Titel
Impact of venous invasion on the efficacy of adjuvant chemotherapy in elderly patients with stage III colorectal cancer
verfasst von
Nobuaki Hoshino
Kenji Kawada
Koya Hida
Saori Goto
Ryuji Uozumi
Suguru Hasegawa
Kenichi Sugihara
Yoshiharu Sakai
Publikationsdatum
01.08.2017
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 8/2017
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-017-0996-0

Weitere Artikel der Ausgabe 8/2017

Medical Oncology 8/2017 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.